Dipeptidyl peptidase-4 inhibition improves endothelial senescence by activating AMPK/SIRT1/Nrf2 signaling pathway
- PMID: 32251672
- DOI: 10.1016/j.bcp.2020.113951
Dipeptidyl peptidase-4 inhibition improves endothelial senescence by activating AMPK/SIRT1/Nrf2 signaling pathway
Abstract
Dipeptidyl peptidase-4 (DPP4) is elevated in numerous cardiovascular pathological processes and DPP4 inhibition is associated with reduced inflammation and oxidative stress. The aim of this study was to examine the role of DPP4 in endothelial senescence. Sprague-Dawley rats (24 months) were orally administrated saxagliptin (10 mg·kg-1·d-1), a DPP4 inhibitor, for 12 weeks in drinking water. Body weight, heart rate, blood glucose, and blood pressure were measured and vascular histological experiments were performed. In vitro studies were performed using H2O2-induced senescent human umbilical vein endothelial cells. Both in vivo and in vitro studies confirmed the elevation of DPP4 in senescent vascular endothelium, and inhibition or knockdown of DPP4 ameliorated endothelial senescence. In addition, DPP4 inhibition or silencing reduced endothelial oxidative stress levels in aging vasculature and senescent endothelial cells. Moreover, DPP4 inhibition or knockdown normalized the expression and phosphorylation of AMP-activated protein kinase-α (AMPKα) and sirtuin 1 (SIRT1) expression. Furthermore, the beneficial effects of DPP4 inhibition or knockdown on endothelial cell senescence were at least partly dependent on SIRT1 and Nrf2 activation. In conclusion, our study demonstrated that DPP4 inhibition or silencing ameliorated endothelial senescence both in vivo and in vitro by regulating AMPK/SIRT1/Nrf2. DPP4 may be a new therapeutic target to combat endothelial senescence.
Keywords: Aging; Dipeptidyl peptidase-4; Endothelium; Oxidative stress; Vascular.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Role of dipeptidyl peptidase-4 as a potentiator of activin/nodal signaling pathway.BMB Rep. 2018 Dec;51(12):636-641. doi: 10.5483/BMBRep.2018.51.12.210. BMB Rep. 2018. PMID: 30463640 Free PMC article.
-
Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A.Arterioscler Thromb Vasc Biol. 2010 Jul;30(7):1407-14. doi: 10.1161/ATVBAHA.110.206425. Epub 2010 May 6. Arterioscler Thromb Vasc Biol. 2010. PMID: 20448207
-
The DPP-IV inhibitor saxagliptin promotes the migration and invasion of papillary thyroid carcinoma cells via the NRF2/HO1 pathway.Med Oncol. 2020 Oct 1;37(11):97. doi: 10.1007/s12032-020-01419-0. Med Oncol. 2020. PMID: 33001278
-
The protective role of DPP4 inhibitors in atherosclerosis.Eur J Pharmacol. 2020 May 15;875:173037. doi: 10.1016/j.ejphar.2020.173037. Epub 2020 Feb 22. Eur J Pharmacol. 2020. PMID: 32097656 Review.
-
Roles and Mechanisms of Dipeptidyl Peptidase 4 Inhibitors in Vascular Aging.Front Endocrinol (Lausanne). 2021 Aug 17;12:731273. doi: 10.3389/fendo.2021.731273. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34489872 Free PMC article. Review.
Cited by
-
NRF2 and the Moirai: Life and Death Decisions on Cell Fates.Antioxid Redox Signal. 2023 Mar;38(7-9):684-708. doi: 10.1089/ars.2022.0200. Epub 2023 Feb 22. Antioxid Redox Signal. 2023. PMID: 36509429 Free PMC article. Review.
-
The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence.Front Pharmacol. 2021 Dec 9;12:731453. doi: 10.3389/fphar.2021.731453. eCollection 2021. Front Pharmacol. 2021. PMID: 34955820 Free PMC article. Review.
-
The potential role of Keap1-Nrf2 pathway in the pathogenesis of Alzheimer's disease, type 2 diabetes, and type 2 diabetes-related Alzheimer's disease.Metab Brain Dis. 2021 Oct;36(7):1469-1479. doi: 10.1007/s11011-021-00762-z. Epub 2021 Jun 15. Metab Brain Dis. 2021. PMID: 34129198 Review.
-
Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis.Front Endocrinol (Lausanne). 2022 Sep 30;13:1007944. doi: 10.3389/fendo.2022.1007944. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36267567 Free PMC article. Review.
-
The OSR9 Regimen: A New Augmentation Strategy for Osteosarcoma Treatment Using Nine Older Drugs from General Medicine to Inhibit Growth Drive.Int J Mol Sci. 2023 Oct 23;24(20):15474. doi: 10.3390/ijms242015474. Int J Mol Sci. 2023. PMID: 37895152 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous